» Articles » PMID: 29422647

Vascular Niche IL-6 Induces Alternative Macrophage Activation in Glioblastoma Through HIF-2α

Overview
Journal Nat Commun
Specialty Biology
Date 2018 Feb 10
PMID 29422647
Citations 132
Authors
Affiliations
Soon will be listed here.
Abstract

Spatiotemporal regulation of tumor immunity remains largely unexplored. Here we identify a vascular niche that controls alternative macrophage activation in glioblastoma (GBM). We show that tumor-promoting macrophages are spatially proximate to GBM-associated endothelial cells (ECs), permissive for angiocrine-induced macrophage polarization. We identify ECs as one of the major sources for interleukin-6 (IL-6) expression in GBM microenvironment. Furthermore, we reveal that colony-stimulating factor-1 and angiocrine IL-6 induce robust arginase-1 expression and macrophage alternative activation, mediated through peroxisome proliferator-activated receptor-γ-dependent transcriptional activation of hypoxia-inducible factor-2α. Finally, utilizing a genetic murine GBM model, we show that EC-specific knockout of IL-6 inhibits macrophage alternative activation and improves survival in the GBM-bearing mice. These findings illustrate a vascular niche-dependent mechanism for alternative macrophage activation and cancer progression, and suggest that targeting endothelial IL-6 may offer a selective and efficient therapeutic strategy for GBM, and possibly other solid malignant tumors.

Citing Articles

Lack of ST2 aggravates glioma invasiveness, vascular abnormality, and immune suppression.

Wicher G, Roy A, Vaccaro A, Vemuri K, Ramachandran M, Olofsson T Neurooncol Adv. 2025; 7(1):vdaf010.

PMID: 39931535 PMC: 11808570. DOI: 10.1093/noajnl/vdaf010.


MYH9 promotes malignant progression of glioma cells through regulating β-catenin stability via epithelial-mesenchymal transition signaling pathway.

Chen Z, Liu C, Zheng W, Li Z, Tang Y, Peng J Sci Rep. 2025; 15(1):4618.

PMID: 39920245 PMC: 11806050. DOI: 10.1038/s41598-025-87151-z.


FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy.

Ni H, Reitman Z, Zou W, Akhtar M, Paul R, Huang M Nat Cancer. 2025; .

PMID: 39910249 DOI: 10.1038/s43018-025-00905-6.


Understanding the Immune System and Biospecimen-Based Response in Glioblastoma: A Practical Guide to Utilizing Signal Redundancy for Biomarker and Immune Signature Discovery.

Jackson L, Erickson A, Camphausen K, Krauze A Curr Oncol. 2025; 32(1).

PMID: 39851932 PMC: 11763554. DOI: 10.3390/curroncol32010016.


Elevated Serum IL-6 as a Negative Prognostic Biomarker in Glioblastoma: Integrating Bioinformatics and Clinical Validation.

Kim S, Kim K, Jung H, Jeong E, Lee H, Kwon J J Cancer. 2025; 16(3):802-811.

PMID: 39781345 PMC: 11705068. DOI: 10.7150/jca.104759.


References
1.
Ghajar C, Peinado H, Mori H, Matei I, Evason K, Brazier H . The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 2013; 15(7):807-17. PMC: 3826912. DOI: 10.1038/ncb2767. View

2.
Martinez F, Gordon S . The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014; 6:13. PMC: 3944738. DOI: 10.12703/P6-13. View

3.
Sica A, Mantovani A . Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012; 122(3):787-95. PMC: 3287223. DOI: 10.1172/JCI59643. View

4.
Bouhlel M, Derudas B, Rigamonti E, Dievart R, Brozek J, Haulon S . PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 2007; 6(2):137-43. DOI: 10.1016/j.cmet.2007.06.010. View

5.
Komohara Y, Ohnishi K, Kuratsu J, Takeya M . Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J Pathol. 2008; 216(1):15-24. DOI: 10.1002/path.2370. View